A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA 19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis [EXTENSION OF 700050940]
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 05 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 20 Jan 2014 Planned End Date changed from 1 Apr 2015 to 1 Jun 2015, according to Clinicaltrials.gov record.